Payment overview · 2025
General Payments
$1,920.50
113 reported records · 21 companies
Healthcare provider profile · identity verified
Timothy Lee Noyes, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CORINTH, MS · NPI 1649294042
Verified facts
What the public records show
CMS Open Payments records show Timothy Lee Noyes, M.D. received $1,920.50 in general payments during 2025 across 113 reported records.
Novo Nordisk Inc accounted for 10.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Korlym, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Trintellix.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Korlym by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $209.07 | 10.9% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $203.35 | 10.6% | 16 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $177.36 | 9.2% | 15 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $174.29 | 9.1% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $169.79 | 8.8% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $166.07 | 8.7% | 8 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $114.38 | 6.0% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $103.32 | 5.4% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $102.48 | 5.3% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $89.86 | 4.7% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $76.71 | 4.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.01 | 3.2% | 3 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $53.70 | 2.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.97 | 2.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.07 | 1.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $26.64 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.96 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.30 | 1.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.61 | 1.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.00 | 1.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.56 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,888.23 | 112 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $174.29 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $169.79 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $146.96 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $128.62 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $114.38 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $108.97 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $108.97 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $102.48 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $101.34 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $100.10 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $94.27 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $94.27 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $89.86 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $88.23 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $81.64 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $76.71 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $66.08 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $56.39 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.39 | 6 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $53.70 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $46.42 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $42.73 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.07 | 2 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $26.64 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 165 | exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 218 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 307 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 27 |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
218 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
307 | 55 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
182 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1309 | 299 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1041 | 230 |
| Ezetimibe | Ezetimibe | 901 | 189 |
| Gabapentin | Gabapentin | 858 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 835 | 180 |
| Omeprazole | Omeprazole | 783 | 166 |
| Levothyroxine Sodium | Levothyroxine Sodium | 718 | 144 |
| Pantoprazole Sodium | Pantoprazole Sodium | 657 | 148 |
| Montelukast Sodium | Montelukast Sodium | 655 | 114 |
| Potassium Chloride | Potassium Chloride | 590 | 108 |
| Carvedilol | Carvedilol | 583 | 102 |
| Lisinopril | Lisinopril | 577 | 116 |
| Metformin Hcl Er | Metformin Hcl | 548 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 512 | 100 |
| Duloxetine Hcl | Duloxetine Hcl | 507 | 99 |
| Hydrochlorothiazide | Hydrochlorothiazide | 440 | 106 |
| Furosemide | Furosemide | 437 | 97 |
| Escitalopram Oxalate | Escitalopram Oxalate | 423 | 89 |
| Losartan Potassium | Losartan Potassium | 399 | 89 |
| Metformin Hcl | Metformin Hcl | 392 | 91 |
| Famotidine | Famotidine | 352 | 82 |
| Sertraline Hcl | Sertraline Hcl | 334 | 67 |
| Trazodone Hcl | Trazodone Hcl | 331 | 69 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 314 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 309 | 83 |
| Ozempic | Semaglutide | 307 | 55 |
| Simvastatin | Simvastatin | 288 | 62 |
| Allopurinol | Allopurinol | 272 | 50 |
| Pioglitazone Hcl | Pioglitazone Hcl | 259 | 50 |
| Buspirone Hcl | Buspirone Hcl | 254 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 250 | 63 |
| Clonazepam | Clonazepam | 240 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 232 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 226 | 39 |
| Donepezil Hcl | Donepezil Hcl | 219 | 40 |
| Mounjaro | Tirzepatide | 218 | 32 |
| Tramadol Hcl | Tramadol Hcl | 206 | 44 |
| Bupropion Xl | Bupropion Hcl | 184 | 33 |
| Eliquis | Apixaban | 182 | 24 |
| Fenofibrate | Fenofibrate | 178 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 178 | 36 |
| Telmisartan | Telmisartan | 178 | 41 |
| Alprazolam | Alprazolam | 175 | 34 |
| Aripiprazole | Aripiprazole | 173 | 40 |
| Meloxicam | Meloxicam | 166 | 40 |
| Jardiance | Empagliflozin | 165 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 160 | 23 |
| Celecoxib | Celecoxib | 158 | 38 |
| Irbesartan | Irbesartan | 146 | 26 |
| Alendronate Sodium | Alendronate Sodium | 145 | 34 |
| Mirtazapine | Mirtazapine | 143 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 142 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 127 | 22 |
| Spironolactone | Spironolactone | 123 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 123 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 121 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 29 |
| Finasteride | Finasteride | 119 | 29 |
| Glimepiride | Glimepiride | 114 | 28 |
| Memantine Hcl | Memantine Hcl | 110 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 28 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 108 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 106 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 106 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 105 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 101 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 28 |
| Bupropion Hcl Sr | Bupropion Hcl | 93 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 91 | 18 |
| Pregabalin | Pregabalin | 89 | 14 |
| Estradiol | Estradiol | 88 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 86 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 26 |
| Warfarin Sodium | Warfarin Sodium | 75 | 12 |
| Nateglinide | Nateglinide | 68 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 67 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 27 |
| Atenolol | Atenolol | 64 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 14 |
| Xarelto | Rivaroxaban | 63 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 62 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 51 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 58 | 17 |
| Lorazepam | Lorazepam | 56 | suppressed |
| Vascepa | Icosapent Ethyl | 55 | 12 |
| Propranolol Hcl | Propranolol Hcl | 54 | 11 |
| Ramipril | Ramipril | 54 | 11 |
| Torsemide | Torsemide | 52 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 51 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 49 | suppressed |
| Olanzapine | Olanzapine | 49 | 13 |
| Ondansetron Odt | Ondansetron | 49 | 22 |
| Eszopiclone | Eszopiclone | 47 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 47 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 46 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Methylprednisolone | Methylprednisolone | 43 | 40 |
| Testosterone Cypionate | Testosterone Cypionate | 43 | 12 |
| Lamotrigine | Lamotrigine | 42 | suppressed |
| Chlorthalidone | Chlorthalidone | 41 | suppressed |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 19 |
| Primidone | Primidone | 40 | 11 |
| Temazepam | Temazepam | 40 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 30 |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 37 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 36 | suppressed |
| Methocarbamol | Methocarbamol | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 23 |
| Valacyclovir | Valacyclovir Hcl | 36 | 17 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Azithromycin | Azithromycin | 33 | 30 |
| Lithium Carbonate | Lithium Carbonate | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 15 |
| Sotalol | Sotalol Hcl | 33 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 32 | 27 |
| Repaglinide | Repaglinide | 32 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | 11 |
| Diazepam | Diazepam | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Novolog | Insulin Aspart | 26 | suppressed |
| Nystatin | Nystatin | 25 | 14 |
| Trulicity | Dulaglutide | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Praluent Pen | Alirocumab | 24 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Metolazone | Metolazone | 16 | 13 |
| Acyclovir | Acyclovir | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Savella | Milnacipran Hcl | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Korlym | Mifepristone | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,920.50 · 113 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, ENROUTE Transcarotid Neuroprotection System, EVENITY, FARXIGA, FREESTYLE LIBRE, FREESTYLE LIBRE 3, JARDIANCE, KISUNLA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SMARTVEST, TRELEGY ELLIPTA, TRINTELLIX, Veozah, Wegovy, YUPELRI, ZENPEP, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error